Biointron Deepens Collaboration with Merck through Global License Agreement for RenMice™ Platform

Beijing, China and Darmstadt, GermanyAugust 25, 2022PR Newswire -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") has entered into a global licensing agreement with Merck for the use of Biocytogen's RenMice™ platform. Under the terms of the agreement, Merck will have full access to Biocytogen's RenMice™ platform to discover and develop fully human antibody therapies targeting an unlimited number of drug targets. Merck will be responsible for all clinical development, manufacturing, and commercialization. Additionally, Merck will pay Biocytogen development and regulatory milestone fees. This formal agreement was reached following an initial evaluation period.

Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen, stated: "This agreement provides Merck with one of the most advanced fully human antibody discovery platforms. We are delighted that Merck recognizes the potential of the RenMice™ mouse platform to accelerate antibody development against novel and challenging targets."